Therapeutic areas in focus
Scratching the surface of eczema care in the UK
Pharmafile speaks to
In light of a recent report by Allergy UK about treatments for eczema patients, we spoke to Head of Clinical Services, Amena Warner, about the future of diagnosis, treatment, and support for this prevalent condition
In the new Allergy UK report, you reported 30 out of 30 healthcare professionals felt there was not adequate mental health support provided for patients with eczema – what measures do you believe are needed to combat this?
There is a need for more awareness of the very significant impact on quality of life, mental health and a person’s lived experience that living with eczema can bring. We believe that psychodermatology services should be commissioned and made more widely available within the new integrated care system/primary care network infrastructure, and attached to secondary/ tertiary dermatology/allergy services to address this need. There are support groups and organisations that can also help, such as Allergy UK, and there is a need for healthcare professionals to direct patients to these sources for ongoing support.
Waiting times for diagnosis, and access to effective treatments, are often lengthy (sometimes even over a year) for eczema patients. How can the healthcare system effectively respond to this statistic?
Prioritisation within the healthcare infrastructure of eczema as a disease area that can be treated and managed effectively, if a correct and timely diagnosis is made with accurate assessment, is key. There is a need for early interventional services and investment into this area. Service provision needs to be addressed and increased to bring down long waiting times.
How does Allergy UK support those living with eczema?
We are the leading patient support and information charity for people living with all kinds of allergies. We have a helpline and webchat with a response team supported by our own clinical team. Our website is also a source of free information, factsheets and leaflets to help support people living with allergic conditions. At the same time, we run masterclasses, and produce videos and podcasts aimed at healthcare professionals on all aspects of allergy, including eczema.
Our work is focused on improving the lives of people impacted by allergic conditions.
What are some of the greatest challenges experienced by people living with eczema, and how have these been exacerbated by COVID-19?
Eczema is a very visual skin condition which can flare and can become very problematic at the most inconvenient times. People often say the itch is the worst aspect, and this often leads to sleepless nights, infection, and scarring of the skin. The huge impact this can have on the individual should not be underestimated, and this is backed up with data from many research studies, as well as what we hear on our helpline. Imagine this on a regular or daily basis and you can begin to understand why so many people affected have difficulty with work/school, with relationships, with concentration, with social situations, etc. Getting an accurate and timely diagnosis can be a challenge for many; as can gaining treatment to control and manage their condition without giving them serious long-term side effects. While COVID-19 has been unkind to everyone, having a condition like eczema can be isolating in itself, causing psychological, as well as physical, distress. The changes in our daily lives caused by COVID-19 are inevitably going to exacerbate those issues. Online consultations are challenging because they do not give a full picture of the condition, and many people are reluctant or embarrassed to expose the full extent of how eczema affects them.
What guidelines would you like to see implemented for better patient outcomes?
We would like to see the prioritisation of the development of NICE guidelines for children, young people, and adults. Also, creating patient pathways for people affected by atopic eczema, with a standardised approach to diagnosis, treatment and management of eczema across the whole of the UK in order to put the patient at the heart of the decisionmaking process for best practice care.
What are your hopes and visions for the future of eczema care and support?
That best practice care, treatment and support be received by those who need it. No one with eczema should feel alone with their condition and the impact it has on their lives. Finally, of course, that a cure will mean that eczema will be eradicated as a health condition.
is Head of Clinical Services at Allergy UK, a national charity that works to raise awareness of allergic disease both nationally and internationally. She took up this appointment after working as a Clinical Nurse Specialist in Immunology and Allergy at an NHS Hospital Trust. She trained at University College Hospital, followed by paediatric training at Great Ormond Street Hospital in London. She also holds a Public Health and Specialist Practice in School Nursing qualification gained in 1994. Visiting schools and carrying out health assessments made Amena very aware of the rising incidence of allergy in the UK and was instrumental in developing her interest in the field.
‘Cumulative life course impairment’: The unforeseen burdens of severe eczema
AbbVie’s Rachael Millward takes a deep dive into dermatitis, patient impact, and patient expectations – and how a healthcare professional might meet them
What are some of the unexpected complexities of skin conditions such as atopic dermatitis?
Atopic dermatitis (AD) is a common chronic inflammatory skin disease with a complex pathogenesis. The severity of the disease varies widely but AD can affect multiple aspects of a patient’s life from the skin manifestations such as the characteristic rash and itching, to less visible impact; such as depression, anxiety, and lack of sleep. AD is what is known as an atopic disease, and is commonly related to other atopic disease such as asthma, allergic rhinitis and in some cases food allergies. Interestingly, Abbvie has conducted a database analysis to further characterise potential comorbidities associated with AD using two distinct databases, CPRD and HES. This analysis has revealed some interesting insights such as observing an increase in the reporting of inflammatory bowel disease as the severity of AD increases. We need to do more research to understand the overlapping immune pathways across the immune mediated diseases to deepen our understanding of such diseases.
AbbVie focuses on dermatological areas with high unmet medical need – which areas within dermatology have you identified on these lines, and why do they qualify?
AbbVie has had long heritage in immunology, but with a dermatology focus for around 20 years. As mentioned AD can have a significant burden on patients lives, added with the complexity of the AD pathogenesis and limited treatment options, there has been a high unmet need for these patients. Some AD patients can be incredibly unwell, with 60% of patients with severe AD talk about their symptoms as unbearable or unrelenting. You can imagine the onward impact of that in terms of things like sleeping, work productivity. For me, focusing on AD and the high unmet need is key and fundamental.
AbbVie also work in delivering treatment areas where current options do not meet patient expectations – can you speak a little on the importance of meeting these expectations, and the current difficulties in delivering on them?
Centrally we need to listen to our patients and understand what they need to do be able to manage their disease. We can assume patients want to be completely free of their disease, however what they actually want could be a good night’s sleep; to wear a dress to go to a wedding or a birthday party; to wake up and feel refreshed and take their kids to school. Small things that can mean a lot to patients. When we look at the patient research we’ve conducted in AD, we often hear patients talk about their desire for freedom from the relentless itching, not being able to sleep, not being able to be productive at work, not being able to concentrate. Patient often talk about feeling embarrassed by their condition, particularly if the rash is on a highly visible areas – on your hands, your face, your legs, skin clearance, for example, could be an ambition we should be aiming towards. At AbbVie, we set out to make a remarkable impact on patients’ lives, and as we innovate and understand immune mediate disease better, we should be asking ourselves: are we meeting the needs of our patients?
What are some of the most serious implications for those who suffer serious chronic skin conditions? How can healthcare professionals work to decrease their severity?
The serious implications are that skin conditions are often dismissed quite early on. One of the biggest barriers for patients, especially for patients with severe skin disease, is being referred to a specialist. Patients can spend a significant period of time in a primary care setting and not receiving the care they require. Sadly some patients may never get to see a specialist, and can drop out of the care system all together, and then we hear of patients self-managing the condition. We need to work in partnership, to allow patients access to a specialist when they need it, and not allow the fact it’s a skin condition to prevent that from happening.
Those patients who do enter into the secondary care system, it’s vital they’re given time with their healthcare professional to talk about how best to manage their conditions as each patient is different and the impact of the disease can vary from patient to patient. Small, but effective, steps, such as educating patients on how to optimise their topical
treatments can be vital. For example, patients are often not given any instruction of how much emollient to use on or how much of the affected skin. Simple steps can really help patients gain control of their disease, however time and resource constraints make this difficult in practice.
But, beyond the healthcare system, certainly the symptomatic relief of the condition itself, and always reminding ourselves that some of these patients have been living with this condition for a very long time and have adapted to cope with the condition. When aiming for holistic care, there are many factors that need to be considered, such as the age of the patient, visible signs and symptoms, and emotional wellbeing. It is well documented that AD can have huge psychological impact on patients, but it is not often part of the management plan. Access to psychodermatology clinics for complex patients have demonstrated significant improvements and have provided patients coping mechanisms to support the management of their disease. Unfortunately, this service is not widely available to the patients who need it. Budget cuts have made it particularly hard for departments to offer this valuable service.
We strive to support patients and healthcare stakeholders to access the Future of Better Care, Quicker; focusing on the need to secure better outcomes for patients by working in partnership with healthcare stakeholders.
Between 11-20% of children in the UK suffer from AD, and 2% of these cases are severe. How are AbbVie working to address this long-term condition, and what are its impacts?
AD has quite a high prevalence in adolescents and children and can manifests itself very early in a patient’s life and the effects of AD on children can have lifelong implications. The concept of cumulative life course impairment is interesting, whereby children with AD may not achieve certain milestones when compared to patients of the same age without AD, because of the profound negative impact of the disease. Educating on this concept and managing the disease early and effectively could reduce the overall impact the disease has on children over the long term.
What recent innovations in the treatments of long-term skin conditions have you been particularly excited by?
It is fantastic to see significant investment being made to advance innovation and management of skin diseases in general, there are myriad skin conditions now being investigated and prioritised, many with significant patient burden and with an associated high unmet need, AD is just one of such conditions.
is currently head of medical affairs for immunology at AbbVie UK, where the team are working on a wide range of immune mediated inflammatory diseases. Rachael has held various roles, across multiple organisations, ranging from clinical research, pharmacovigilance, medical information, and latterly medical affairs. Rachael’s academic background and research interests are in biotechnology and molecular genetics with a particular focus on pluripotent stem cells. For more information, contact: